AR058194A1 - Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide - Google Patents

Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide

Info

Publication number
AR058194A1
AR058194A1 ARP060105053A ARP060105053A AR058194A1 AR 058194 A1 AR058194 A1 AR 058194A1 AR P060105053 A ARP060105053 A AR P060105053A AR P060105053 A ARP060105053 A AR P060105053A AR 058194 A1 AR058194 A1 AR 058194A1
Authority
AR
Argentina
Prior art keywords
corticoesteroid
drugs
antimuscarinic agent
medicament
inflammatory
Prior art date
Application number
ARP060105053A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR058194A1 publication Critical patent/AR058194A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Un medicamento que comprende, en forma separada o en conjunto, (A) una sal de glicopirronio y (B) furoato de mometasona, para administracion simultánea, secuencial o separada en el tratamiento de una enfermedad inflamatoria u obstructiva de las vías respiratorias.
ARP060105053A 2005-11-21 2006-11-17 Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide AR058194A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0523653.4A GB0523653D0 (en) 2005-11-21 2005-11-21 Organic compounds

Publications (1)

Publication Number Publication Date
AR058194A1 true AR058194A1 (es) 2008-01-23

Family

ID=35580402

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105053A AR058194A1 (es) 2005-11-21 2006-11-17 Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide

Country Status (14)

Country Link
US (1) US20080317862A1 (es)
EP (1) EP1954266A1 (es)
JP (1) JP2009516662A (es)
KR (1) KR20080069196A (es)
CN (1) CN101312721A (es)
AR (1) AR058194A1 (es)
AU (1) AU2006314723A1 (es)
BR (1) BRPI0618807A2 (es)
CA (1) CA2630224A1 (es)
GB (1) GB0523653D0 (es)
PE (1) PE20071081A1 (es)
RU (1) RU2008124825A (es)
TW (1) TW200803840A (es)
WO (1) WO2007057222A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
LT2435023T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Kompozicijos, skirtos ilgai veikiančių muskarininių antagonistų ir ilgai veikiančių beta-2-adrenerginio receptoriaus agonistų pristatymui į plaučius, ir susiję būdai bei sistemos
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
TWI495468B (zh) 2009-12-23 2015-08-11 Chiesi Farma Spa 治療慢性阻塞性肺病（ｃｏｐｄ）之醫藥組成物
ES2468835T3 (es) 2009-12-23 2014-06-17 Chiesi Farmaceutici S.P.A. Terapia combinada para EPOC
EP2749284A3 (en) 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and carmoterol
FR2987266B1 (fr) * 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
CN110403922A (zh) * 2013-01-28 2019-11-05 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
ES2699257T3 (es) 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2015008205A2 (en) * 2013-07-13 2015-01-22 Mahesh Kandula Compositions and methods for the treatment of respiratory diseases
MX368835B (es) 2013-12-30 2019-10-18 Chiesi Farm Spa Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol.
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
AU2019477296A1 (en) 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP1333830A2 (de) * 2000-10-31 2003-08-13 Boehringer Ingelheim Pharma GmbH & Co.KG Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden
CN100569235C (zh) * 2004-02-06 2009-12-16 Meda制药有限及两合公司 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合
EP1713472A2 (en) * 2004-02-06 2006-10-25 MEDA Pharma GmbH & Co. KG Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
JP2008534611A (ja) * 2005-03-30 2008-08-28 シェーリング コーポレイション 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法

Also Published As

Publication number Publication date
CA2630224A1 (en) 2007-05-24
CN101312721A (zh) 2008-11-26
US20080317862A1 (en) 2008-12-25
RU2008124825A (ru) 2009-12-27
EP1954266A1 (en) 2008-08-13
BRPI0618807A2 (pt) 2011-09-13
GB0523653D0 (en) 2005-12-28
KR20080069196A (ko) 2008-07-25
TW200803840A (en) 2008-01-16
AU2006314723A1 (en) 2007-05-24
WO2007057222A1 (en) 2007-05-24
PE20071081A1 (es) 2007-12-11
JP2009516662A (ja) 2009-04-23

Similar Documents

Publication Publication Date Title
AR058194A1 (es) Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide
CL2007002526A1 (es) Un medicamento que comprende, separado o juntos: a) una sal de glicopirronio; b) un agonista del adreno-receptor beta-2 seleccionado de salmeterol y formoterol; y c) un corticosteroide; kit farmaceutico; y uso en el tratamiento de una enfermedad infl
CL2004001170A1 (es) Combinacion farmaceutica inhalable que contiene (a) formoterol, o una sal, o un solvato de el o de la sal y (b) furoato de mometasona; estuche farmaceutico que la comprende; y su uso en la terapia de una enfermedad inflamatoria u obstructiva de las v
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
AR057904A1 (es) Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
ID29181A (id) Kombinasi formoterol dan garam tiotropium
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
AR022609A1 (es) Combinaciones de un agonista de beta-2 y un esteroide
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
BRPI0814957A2 (pt) Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
AR054253A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
ECSP078014A (es) Regimen de dosificacion para prasugrel
CL2007002878A1 (es) Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
UY27564A1 (es) Combinación farmacéutica.
CL2004000319A1 (es) Combinacion farmaceutica que comprende edotecarina o una sal farmaceuticamente aceptable y docetaxel o capacitabina, kit terapeutico, util para el tratamiento del cancer.
AR045177A1 (es) Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave

Legal Events

Date Code Title Description
FA Abandonment or withdrawal